» Articles » PMID: 34888413

A Cross-sectional Study of Patients and Physicians on the Impact of Myeloproliferative Neoplasms on Patient Health: The Landmark Survey From Taiwan

Overview
Journal J Patient Exp
Specialty Health Services
Date 2021 Dec 10
PMID 34888413
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with myeloproliferative neoplasm (MPN), including myelofibrosis, polycythemia vera, and essential thrombocythemia, experience a pronounced symptom burden. This study aimed to collect information from physicians and patients in Taiwan to explore their perceptions regarding MPN, treatment goals, and satisfaction with disease management. A cross-sectional, online survey was conducted among patients and physicians from September 2018 to November 2018 in Taiwan as a subset of the expansion of the Landmark survey. Overall, 50 patients with MPN and 30 physicians participated in this study. The symptom burden was low, with the mean number of symptoms experienced being 1.8. The most frequent symptom per physicians' perception was fatigue, whereas it is not the most common symptom from MPN patients' perspective. Blood count was the key indicator to determine treatment success from patients' view, whereas presence of a new symptom was the key indicator from physicians' perspective. Concordant with previous studies, our study revealed a lack of alignment between physician and patient perceptions relating to treatment goals and disease management. Nevertheless, the physical, emotional, work/activities and financial impacts on patients were minimal in Taiwan.

Citing Articles

Burden of Symptoms and Symptom Experience of Filipino Patients with Myeloproliferative Neoplasm: A Qualitative Phenomenological Approach.

Mesina F, Dumagay T, Alejandria M, Castillo-Carandang N Acta Med Philipp. 2024; 58(18):35-48.

PMID: 39483305 PMC: 11522347. DOI: 10.47895/amp.vi0.8272.


Physician Perceptions of the Clinical, Economic and Humanistic Burden of Disease and Unmet Needs in Myelofibrosis: Preliminary Findings from the MPN Landmark Survey in Indonesia.

Pandji I, Hardianti M, Tubagus A, Wibawa R, Hogg L, Tan K Asian Pac J Cancer Prev. 2023; 24(8):2837-2843.

PMID: 37642072 PMC: 10685220. DOI: 10.31557/APJCP.2023.24.8.2837.


Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the TouchStone SM Patient Survey.

Mesa R, Sullivan E, Dubinski D, Carroll B, Slee V, Jennings S Cancer. 2022; 128(20):3691-3699.

PMID: 35996873 PMC: 9804682. DOI: 10.1002/cncr.34420.


Perceptions of patient disease burden and management approaches in systemic mastocytosis: Results of the TouchStone Healthcare Provider Survey.

Mesa R, Sullivan E, Dubinski D, Carroll B, Slee V, Jennings S Cancer. 2022; 128(20):3700-3708.

PMID: 35996871 PMC: 9804550. DOI: 10.1002/cncr.34421.

References
1.
Ballen K, Shrestha S, Sobocinski K, Zhang M, Bashey A, Bolwell B . Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2009; 16(3):358-67. PMC: 2908949. DOI: 10.1016/j.bbmt.2009.10.025. View

2.
Barbui T, Tefferi A, Vannucchi A, Passamonti F, Silver R, Hoffman R . Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018; 32(5):1057-1069. PMC: 5986069. DOI: 10.1038/s41375-018-0077-1. View

3.
Mesa R, Miller C, Thyne M, Mangan J, Goldberger S, Fazal S . Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016; 16:167. PMC: 4769833. DOI: 10.1186/s12885-016-2208-2. View

4.
Harrison C, Mathias J, Campbell-Drew M, Mead A, Pemberton-Whiteley Z, Ali S . UK results from the myeloproliferative neoplasms (MPN) landmark survey on the symptom, emotional and economic burden of MPN. Br J Haematol. 2019; 186(3):e1-e4. DOI: 10.1111/bjh.15839. View

5.
Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View